NEW YORK, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.
Dr. Chain's presentation, which begins at 10:00 am local time on March 12 th, features the company's CONJUMAB platform technology, including its lead compound, CONJUMAB-A, an antibody drug conjugate being developed for age-related macular degeneration (AMD) as well as the company's tau antibody technology. Dr. Chain will also be attending the 11 th Annual Conference on Alzheimer's disease and Parkinson's disease from March 6-10 in Florence, Italy.
"We discovered a novel way to attack certain types of complex diseases through the use of antibody drug conjugates (ADCs) in which two different molecules - an antibody targeting an amyloidogenic polypeptide and a small neuroprotective molecule - are combined chemically into a single entity," said Dr. Daniel Chain, the inventor of CONJUMAB. "The antibody has a chaperone-like role in clearing the amyloid while the small molecule reduces the neurotoxicity caused by the peptide. Our lead drug candidate CONJUMAB-A, capitalizes on recent insights linking the mechanisms that contribute to the pathogenesis of AMD and Alzheimer's disease, especially the role of oxidative stress and amyloid beta (Aβ) which is believed to be an essential mediator in the progression of dry AMD to wet AMD."Traditionally, ADCs have been used to deliver a cytotoxic payload to kill cancer cells. By contrast, drugs based on CONJUMAB are comprised of antibodies targeting amyloidogenic polypeptides that would be linked chemically to a small molecule that is non-toxic and instead confers cytoprotective properties such as an antioxidant or anti-inflammatory molecule. CONJUMAB-A is comprised of a humanized monoclonal antibody against beta amyloid (Aβ) conjugated to melatonin, a potent antioxidant molecule with anti-amyloidogenic, anti-inflammatory and anti-apoptotic properties with the aim of preventing the accumulation of toxic Aβ in the retina and delivering on-site neuroprotection to reduce geographical atrophy and neovascularization.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV